About: Elevations of serum cancer biomarkers correlate with severity of COVID‐19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Elevations of serum cancer biomarkers correlate with severity of COVID‐19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Elevations of serum cancer biomarkers correlate with severity of COVID‐19
Creator	Wang, Hui Cao, Xiaoling Su, Jingyu Tan, Wenbin Wan, Huimin Wei, Jiazhou Wei, Xiuqi Yang, Kunyu
Source	Medline; PMC
abstract	In this retrospective study, we evaluated the levels of a series of serum biomarkers in coronavirus disease 2019 (COVID‐19) patients (mild: 131; severe: 98; critical: 23). We found that there were significant increases in levels of human epididymis protein 4 (HE4) (73.6 ± 38.3 versus 46.5 ± 14.7, p<0.001), cytokeratin‐19 fragment (CYFRA21‐1) (2.2 ± 0.9 versus 1.9 ± 0.8, p<0.001), carcinoembryonic antigen (CEA) (3.4 ± 2.2 versus 2.1 ± 1.2, p<0.001), carbohydrate antigens (CA) 125 (18.1 ± 13.5 versus 10.5 ± 4.6, p<0.001) and 153 (14.4 ± 8.9 versus 10.1 ± 4.4, p<0.001) in COVID‐19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases (HE4, CYFRA21‐1 and CA125: p<0.001; CEA and CA153: p<0.01). Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID‐19 as compared with mild and severe cases and normal controls (p<0.01). There were positive associations between levels of C‐reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21‐1(R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID‐19, demonstrating diffuse and acute lung injuries. This article is protected by copyright. All rights reserved.
has issue date	2020-04-29(xsd:dateTime)
bibo:doi	10.1002/jmv.25957
bibo:pmid	32347972
has license	no-cc
sha1sum (hex)	1f2ac1962470a0b7888ed913363c5cc5fad35670
schema:url	https://doi.org/10.1002/jmv.25957
resource representing a document's title	Elevations of serum cancer biomarkers correlate with severity of COVID‐19
has PubMed Central identifier	PMC7267262
has PubMed identifier	32347972
schema:publication	J Med Virol
resource representing a document's body	covid:1f2ac1962470a0b7888ed913363c5cc5fad35670#body_text
is schema:about of	named entity 'subjects' named entity 'COVID-19' named entity 'ANTIGENS' named entity 'FOUND' named entity 'CYFRA21-1' named entity 'SERUM BIOMARKERS' named entity 'retrospective study' named entity 'mild' named entity 'coronavirus disease 2019' named entity 'CA125' named entity 'levels' named entity 'CEA' named entity 'biomarkers' named entity '2.2' named entity 'serum' named entity 'retrospective study' named entity 'HE4' named entity 'control subjects' named entity 'COVID-19' named entity 'CEA' named entity 'lungs' named entity 'lung' named entity 'HE4' named entity 'COVID' named entity 'WBC' named entity 'Parkinson's disease' named entity 'lungs' named entity 'lung' named entity 'mortality rate' named entity 'bat' named entity 'diarrhea' named entity 'zoonotic origin' named entity 'animal model' named entity 'replicases' named entity 'standard deviation' named entity 'coronavirus' named entity 'HE4' named entity 'CEA' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'ACE2' named entity 'headache' named entity 'epidermal growth factor receptor' named entity 'genome' named entity 'fatigue' named entity 'antigens' named entity 'phylogeny' named entity 'COVID' named entity 'evolution' named entity 'COVID' named entity 'molecular basis' named entity 'IL-6' named entity 'fever' named entity 'CEA' named entity 'biomarkers' named entity 'biomarkers' named entity 'lung' named entity 'NSE' named entity 'inflammatory conditions' named entity 'control group' named entity 'statistical significance' named entity 'multiple organ failure' named entity 'COVID' named entity 'HE4' named entity 'control group' named entity 'pneumonia' named entity 'biomarkers' named entity 'alveolar' named entity 'biomarkers' named entity 'lungs' named entity 'coronavirus' named entity 'blood oxygen saturation' named entity 'Armonk' named entity 'SARS' named entity 'tumorigenesis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software